LLY Eli Lilly's revenue soared 45% year-over-year to $13.5 billion, surpassing expectations by $100 million. This growth was fueled by strong sales of Mounjaro ($3.5 billion) and Zepbound ($1.9 billion), both aligning with pre-announced figures. Although sales fell short of initial projections in the previous quarter, the company's FY25 revenue guidance of $58-61 billion (+32% Y/Y) reassured investors. Management highlighted a planned 60% increase in GLP-1 supply during the first half of 2025 to meet rising demand, while the removal of Mounjaro and Zepbound from the FDA’s shortage list is expected to limit compounded alternatives and strengthen Lilly’s market dominance.
With recent regulatory approvals for Kisunla and Ebglyss, expanded global rollouts for Mounjaro, and ongoing reimbursement negotiations for Zepbound, Lilly continues to reinforce its leadership in the obesity and diabetes space. Management remains optimistic about long-term growth, citing the need for further capacity expansion to keep pace with demand. The next major catalyst will be mid-year Phase 3 trial results for Orforglipron, Lilly’s oral obesity treatment.